This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pfizer, BioNTech face continued UPC infringement suit over Covid vaccine patent

( April 17, 2025, 14:57 GMT | Official Statement) -- MLex Summary: The Unified Patent Court has ruled that the patent infringement case brought by Promosome against Pfizer and BioNTech — over its EP 2,401,365 used in Comirnaty Covid-19 vaccine variants — will proceed. While the defendants challenged the court's jurisdiction over one vaccine version — Comirnaty Original/Omicron BA.1 — allegedly sold only before the UPC’s June 1, 2023 start date, the judge decided the objection will be dealt with in the main proceedings. The Munich Local Division confirmed it has jurisdiction for the remaining vaccine variants sold after that date.See UPC order attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections